Previous 10 | Next 10 |
DermTech , Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced its presentation at the Biomarkers & Precision Medicine USA Congress, held from Oct. ...
DermTech , Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced its presentation at Outsourcing in Clinical Trials Southern California , held from Sept. ...
Lemonade (NYSE: LMND) and DermTech (NASDAQ: DMTK) have both found themselves in tricky financial situations. The reward still might outweigh the risk for these two beaten-down stocks. *Stock prices used were the midday prices of Sept. 1, 2022. The video was publish...
Summary Today, we take our first look at DermTech, Inc., a small molecular testing concern. The company is seeing some sales traction and the stock sells for less than cash value, but DermTech's cash burn rate is more than concerning. A full investment analysis of DermTech fol...
DermTech ( NASDAQ: DMTK ) stock plummeted ~32% after Q2 net loss widened and the company lowered its FY22 assay revenue outlook. DermTech CEO John Dobak said that in Q2 the company streamlined its laboratory processes, which reduced the per unit cost for its ...
Gainers: Verona Pharma VRNA +87% . Mersana Therapeutics ( MRSN ) +38% . GoodRx Holdings ( GDRX ) +19% . Atara Biotherapeutics ( ATRA ) +22% . Heron Therapeutics HRTX +16% . Losers: CorMedix ( CRMD ) -56% . Qu...
DermTech, Inc. (DMTK) Q2 2022 Earnings Conference Call August 08, 2022 05:00 PM ET Company Participants Steve Kunszabo - Head of Investor Relations John Dobak - President & Chief Executive Officer Kevin Sun - Chief Financial Officer Conference Call Part...
DermTech press release ( NASDAQ: DMTK ): Q2 GAAP EPS of -$0.99 beats by $0.02 . Revenue of $4.23M (+35.6% Y/Y) misses by $0.58M . Shares -3.9% . Cash, cash equivalents, restricted cash and short-term marketable securities were $177.4 million as of June ...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its second-quarter 2022 financial results and updated its full-year 2022 outlook. “We co...
Major earnings expected after the bell on Monday include: 3D Systems ( DDD ) Lemonade ( LMND ) Novavax ( NVAX ) Take-Two Interactive Software ( TTWO ) Upstart Holdings ( UPST ) For further details see: Notable earnings after Monday's close...